Karius
Bill has over 20 years of financial expertise, including extensive experience raising capital for growth organizations. Prior to joining Karius, he helped build the finance team at Freenome, an innovative liquid biopsy company. Before moving into the diagnostics industry, Bill was an award-winning equity analyst at RBC Capital Markets and Piper Sandler, leading its healthcare research team. He also helped raise nearly $8B in growth capital for top Diagnostics and Life Science Tools companies during his tenure on Wall Street. Bill completed his MBA at the University of Minnesota’s Carlson School of Management and holds the CFA designation.
This person is not in any offices
Karius
2 followers
Karius sees a world where infectious disease is no longer a major threat to human health. To achieve this, the Karius Test enables mapping of the patient’s microbial landscape from a single blood sample to enable physicians to make rapid treatment decisions.